PSD502, contains a mixture of lidocaine and prilocaine + Placebo
Phase 2/3Completed 0 watching 0 views this weekπ Rising
65
Development Stage
β
Pre-clinicalβ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Premature Ejaculation
Conditions
Premature Ejaculation
Trial Timeline
Oct 1, 2007 β Oct 1, 2009
NCT ID
NCT00556478About PSD502, contains a mixture of lidocaine and prilocaine + Placebo
PSD502, contains a mixture of lidocaine and prilocaine + Placebo is a phase 2/3 stage product being developed by Shionogi for Premature Ejaculation. The current trial status is completed. This product is registered under clinical trial identifier NCT00556478. Target conditions include Premature Ejaculation.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00556478 | Phase 2/3 | Completed |
Competing Products
8 competing products in Premature Ejaculation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| dapoxetine | Yuhan | Phase 1/2 | 41 |
| Placebo + Cisapride | Johnson & Johnson | Approved | 85 |
| SHR7280οΌGanirelix Acetate Injection simulant + SHR7280 simulantοΌ Ganirelix Acetate Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ranolazine | Gilead Sciences | Phase 2 | 51 |
| IX-01 + Placebo | ICON plc. | Phase 2 | 49 |
| Flecainide (monotherapy) | Brain Biotech | Pre-clinical | 15 |
| Tramadol Hydrochloride & Placebo | Bausch Health | Phase 3 | 72 |
| Tramadol Hydrochloride + Placebo | Bausch Health | Phase 3 | 72 |